Hep C, all the cool kids are treating it

Gilead isn’t the only Hep C game in town but, to date, has held strong to its first-mover advantage. According to a recent article in Investor’s Business Daily, that may soon change. And not because of a lower price. AbbVie’s competitive offering will still list for around $28,000 per month. Its competitive advantage lies in its 4-week shorter treatment regimen. Also, AbbVie’s glecaprevir and pibrentasvir drug combo is likely to be approved with few conditions. Where Gilead’s treatment combo is a 12-week regimen for patients who have not previously responded to a single drug treatment, AbbVie’s combo is taken for only 8 weeks and will probably be approved as a first-line treatment. “Aw, crap,” thought someone at Gilead, probably.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn